Raltegravir Pharmacokinetics in Patients on Asunaprevir-Daclatasvir

Aurélie Barrail-Tran; Corine Vincent; Valérie Furlan; Isabelle Rosa; Eric Rosenthal; Antoine Cheret; Jean-Michel Molina; Anne-Marie Taburet; Lionel Piroth; ANRS HC30 QUADRIH Study Group

doi:10.1128/AAC.01603-15

Raltegravir Pharmacokinetics in Patients on Asunaprevir-Daclatasvir

Antimicrob Agents Chemother. 2015 Dec;59(12):7903-5. doi: 10.1128/AAC.01603-15. Epub 2015 Oct 5.

Authors

Aurélie Barrail-Tran¹, Corine Vincent², Valérie Furlan³, Isabelle Rosa⁴, Eric Rosenthal⁵, Antoine Cheret⁶, Jean-Michel Molina⁷, Anne-Marie Taburet⁸, Lionel Piroth⁹; ANRS HC30 QUADRIH Study Group

Affiliations

¹ AP-HP, Hôpital Bicêtre, Pharmacie Clinique, Le Kremlin Bicêtre, France Université Paris Sud, INSERM UMR 1184, Center for Immunology of Viral Infections and Autoimmune Diseases, Le Kremlin Bicêtre, France aurelie.barrail-tran@bct.aphp.fr.
² INSERM SC10-US019, Villejuif, France.
³ AP-HP, Hôpital Bicêtre, Pharmacie Clinique, Le Kremlin Bicêtre, France.
⁴ Centre Hospitalier Intercommunal, Service d'Hépato-Gastro-Entérologie, Créteil, France.
⁵ CHU de Nice, Hôpital de l'Archet, Service de Médecine Interne, Nice, France.
⁶ CH de Tourcoing Hôpital Gustave Dron, SRU Maladies Infectieuses et du Voyageur, Tourcoing, France.
⁷ Hôpital Saint Louis Université Paris Diderot, Service des Maladies Infectieuses et Tropicales, Paris, France.
⁸ AP-HP, Hôpital Bicêtre, Pharmacie Clinique, Le Kremlin Bicêtre, France Université Paris Sud, INSERM UMR 1184, Center for Immunology of Viral Infections and Autoimmune Diseases, Le Kremlin Bicêtre, France.
⁹ Infectious Diseases Department, Centre Hospitalo-Universitaire, and UMR 1347, Université de Bourgogne, Dijon, France.

Abstract

Raltegravir pharmacokinetics was studied in 20 patients included in the ANRS HC30 QUADRIH Study before and after addition of anti-hepatitis C virus (anti-HCV) quadritherapy, including pegylated-interferon-ribavirin and asunaprevir plus daclatasvir. Raltegravir pharmacokinetic parameters remained unchanged whether administered on or off anti-HCV therapy. In addition, concentrations of raltegravir, asunaprevir, and daclatasvir were not affected by liver cirrhosis. These data suggest that in human immunodeficiency virus (HIV)-HCV-coinfected patients, whether cirrhotic or not, asunaprevir and daclatasvir could be administered safely with raltegravir.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adult
Antiviral Agents / therapeutic use*
Carbamates
Coinfection
Drug Therapy, Combination
Female
HIV Infections / drug therapy*
HIV Infections / pathology
HIV Infections / virology
HIV-1 / drug effects
HIV-1 / physiology
Hepacivirus / drug effects
Hepacivirus / physiology
Hepatitis C, Chronic / drug therapy*
Hepatitis C, Chronic / pathology
Hepatitis C, Chronic / virology
Humans
Imidazoles / therapeutic use*
Interferon-alpha / therapeutic use
Isoquinolines / therapeutic use*
Liver / drug effects
Liver / pathology
Liver / virology
Liver Cirrhosis / drug therapy
Liver Cirrhosis / pathology
Liver Cirrhosis / virology
Male
Middle Aged
Polyethylene Glycols / therapeutic use
Pyrrolidines
Raltegravir Potassium / pharmacokinetics*
Raltegravir Potassium / therapeutic use
Recombinant Proteins / therapeutic use
Ribavirin / therapeutic use
Sulfonamides / therapeutic use*
Valine / analogs & derivatives

Substances

Antiviral Agents
Carbamates
Imidazoles
Interferon-alpha
Isoquinolines
Pyrrolidines
Recombinant Proteins
Sulfonamides
Polyethylene Glycols
Raltegravir Potassium
Ribavirin
Valine
daclatasvir
peginterferon alfa-2a
asunaprevir